6-Methoxy-7-[2-(4-methylpiperazin-1-yl)-ethoxy]-4-(benzothiazol-2-ylamino)-quinoline-3-carbonitrile | 947339-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-Methoxy-7-[2-(4-methylpiperazin-1-yl)-ethoxy]-4-(benzothiazol-2-ylamino)-quinoline-3-carbonitrile
• 英文别名: 4-(1,3-benzothiazol-2-ylamino)-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile
• CAS: 947339-90-4
• 化学式: C₂₅H₂₆N₆O₂S
• 分子量: 474.586
• InChiKey: JRTQUEQNWQYBSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 7-(2-chloroethoxy)-6-methoxy-4-(benzothiazol-2-ylamino)-quinoline-3-carbonitrile 在 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以49%的产率得到6-Methoxy-7-[2-(4-methylpiperazin-1-yl)-ethoxy]-4-(benzothiazol-2-ylamino)-quinoline-3-carbonitrile
  参考文献：
  名称：

  Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase

  摘要：

  Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heteroarylamino-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, prepared, and evaluated for blocking multiple signaling pathways in cancer therapy. All compounds were evaluated by two related enzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compounds could inhibit both enzymes, and several of them showed potent inhibition activity against different cancer cell lines. The best compound 20 (CPU-Y020) showed the IC(50) values of 6.58 and 7.61 mu M toward colon cancer HT-29 and liver cancer HepG2 cell lines. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.04.065

文献信息

• Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase
  作者：Xin Cao、Qi-Dong You、Zhi-Yu Li、Qing-Long Guo、Jing Shang、Ming Yan、Ji-Wang Chern、Men-Ling Chen

  DOI：10.1016/j.bmc.2008.04.065

  日期：2008.6

  Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heteroarylamino-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, prepared, and evaluated for blocking multiple signaling pathways in cancer therapy. All compounds were evaluated by two related enzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compounds could inhibit both enzymes, and several of them showed potent inhibition activity against different cancer cell lines. The best compound 20 (CPU-Y020) showed the IC(50) values of 6.58 and 7.61 mu M toward colon cancer HT-29 and liver cancer HepG2 cell lines. (C) 2008 Elsevier Ltd. All rights reserved.